Immuno-Oncology | Specialty

Novel Pembrolizumab Combos Show Promising Responses in Melanoma

November 21st 2015

Two separate early phase clinical trials exploring pembrolizumab-containing immunotherapy combinations have shown objective response rates over 50% in patients with advanced melanoma.

Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

November 21st 2015

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab Combination

November 21st 2015

Victoria Atkinson, MD, of Princess Alexandra Hospital and Gallipoli Medical Research Foundation, Queensland, discusses long-term data from the phase III CheckMate-066 trial.

James Allison Predicts 'Cures' With Checkpoint Inhibitor Combinations

November 20th 2015

Since the approval of the first checkpoint inhibitor, ipilimumab, several combinations and monotherapies have gained rapid approval, with continued expansion on the horizon.

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma

November 20th 2015

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

November 20th 2015

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Dr. Reardon on Updated Data From the Phase II ReACT Trial

November 20th 2015

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response

November 20th 2015

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

Testing Checkpoint Inhibitors in Brain Cancer Requires Careful AE Management

November 20th 2015

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Nivolumab Survival Benefit Sustained in Long-Term Melanoma Data

November 20th 2015

Long-term data continue to show sustained improvements in overall survival with nivolumab alone or in combination with ipilimumab as a frontline treatment for patients with advanced melanoma.

QoL Similar With Checkpoint Combo Versus Single-Agents in Melanoma

November 19th 2015

There were few differences in quality of life, global health, and symptom burden between patients with melanoma who were treated with nivolumab plus ipilimumab or either agent alone.

Researchers Seek to Improve Responses With Checkpoint Inhibitors

November 19th 2015

Predictive genetic signatures and novel combination strategies may be the key to improving the often dramatic responses seen with immune checkpoint inhibitors.

Sheri Holmen on Understanding Drivers of Melanoma Metastasis

November 19th 2015

Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

New Treatments for Novel Targets Next Step in Immuno-Oncology Revolution

November 19th 2015

There is a wide variety of novel targets and corresponding checkpoint and immune blocker/activator therapies that may soon show promise in cancer care.

Checkpoint Inhibitors Generate Renewed Excitement in RCC

November 18th 2015

With several novel therapies approaching regulatory approval, the treatment landscape for renal cell carcinoma is facing a major upheaval.

FDA Panel Rejects Immunotherapy MCNA in Bladder Cancer

November 18th 2015

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-GuÃ©rin therapy.

Avelumab Receives Breakthrough Therapy Designation for Merkel Cell Carcinoma

November 18th 2015

The FDA has granted a breakthrough therapy designation to avelumab as a potential treatment for patients with metastatic Merkel cell carcinoma following progression on at least one prior chemotherapy regimen.

FDA Grants Priority Review to Nivolumab for Renal Cell Carcinoma

November 16th 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for patients with advanced renal cell carcinoma following prior antiangiogenic therapy.

Promising Immunotherapy Agents on Horizon in Bladder Cancer

November 16th 2015

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy

November 13th 2015

Roswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.